BR112022027069A2 - Agente terapêutico para o câncer de mama - Google Patents

Agente terapêutico para o câncer de mama

Info

Publication number
BR112022027069A2
BR112022027069A2 BR112022027069A BR112022027069A BR112022027069A2 BR 112022027069 A2 BR112022027069 A2 BR 112022027069A2 BR 112022027069 A BR112022027069 A BR 112022027069A BR 112022027069 A BR112022027069 A BR 112022027069A BR 112022027069 A2 BR112022027069 A2 BR 112022027069A2
Authority
BR
Brazil
Prior art keywords
therapeutic agent
breast cancer
benzamido
methoxyethoxy
piperidin
Prior art date
Application number
BR112022027069A
Other languages
English (en)
Inventor
Kawano Satoshi
Miyano Saori
Nishibata Kyoko
Fukushima Sayo
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112022027069A2 publication Critical patent/BR112022027069A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

AGENTE TERAPÊUTICO PARA O CÂNCER DE MAMA. Descreve-se um agente terapêutico para o câncer de mama, o referido agente terapêutico compreendendo 5-((2-(4-(1-(2-hidroxietil)piperidin-4-il)benzamido)piridin-4-il)oxi)-6-(2-metoxietoxi)-N-metil-1H-indolo-1-carboxamida ou um sal farmacologicamente aceitável da mesma, para ser administrado em combinação com um antagonista dos receptores de estrogênio ou um inibidor da aromatase.
BR112022027069A 2020-07-31 2021-07-29 Agente terapêutico para o câncer de mama BR112022027069A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020130935 2020-07-31
JP2020163258 2020-09-29
PCT/JP2021/028008 WO2022025150A1 (ja) 2020-07-31 2021-07-29 乳がん治療剤

Publications (1)

Publication Number Publication Date
BR112022027069A2 true BR112022027069A2 (pt) 2023-02-07

Family

ID=80035757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022027069A BR112022027069A2 (pt) 2020-07-31 2021-07-29 Agente terapêutico para o câncer de mama

Country Status (11)

Country Link
US (1) US20230172924A1 (pt)
EP (1) EP4151212A4 (pt)
JP (1) JPWO2022025150A1 (pt)
KR (1) KR20230047056A (pt)
CN (1) CN115996722A (pt)
AU (1) AU2021315234A1 (pt)
BR (1) BR112022027069A2 (pt)
CA (1) CA3185174A1 (pt)
MX (1) MX2023000060A (pt)
TW (1) TW202220652A (pt)
WO (1) WO2022025150A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116293A1 (en) * 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
CN115177619A (zh) * 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
JP2018022750A (ja) 2016-08-02 2018-02-08 太陽誘電株式会社 積層セラミックコンデンサ
CN111712245A (zh) 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂
US20230149381A1 (en) * 2020-04-17 2023-05-18 Eisai R&D Management Co., Ltd. Breast cancer therapeutic agent

Also Published As

Publication number Publication date
AU2021315234A1 (en) 2023-01-19
KR20230047056A (ko) 2023-04-06
CN115996722A (zh) 2023-04-21
TW202220652A (zh) 2022-06-01
CA3185174A1 (en) 2022-02-03
WO2022025150A1 (ja) 2022-02-03
US20230172924A1 (en) 2023-06-08
EP4151212A4 (en) 2024-04-10
JPWO2022025150A1 (pt) 2022-02-03
MX2023000060A (es) 2023-02-01
EP4151212A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
Comstock et al. Targeting cell cycle and hormone receptor pathways in cancer
Ashton et al. Oxidative phosphorylation as an emerging target in cancer therapy
Konstantinidou et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non–small cell lung cancer harboring K-RAS mutations
Finch et al. Toenail onychomycosis: current and future treatment options
RU2015134558A (ru) Моноциклическое пиридиновое производное
Ford et al. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (IKur): rationale, pharmacology and evidence for potential therapeutic value
Bruen et al. Baseline factors predictive of SLT response: a prospective study
MX2017009892A (es) Agente terapeutico contra el colangiocarcinoma.
RU2016112542A (ru) Новые активаторы растворимой гуанилатциклазы и их применение
NZ513204A (en) Quinazoline derivatives as angiogenesis inhibitors
PE20110929A1 (es) Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor 2 adrenergico
NZ603231A (en) Cgrp receptor antagonist and its use for treating conditions such as migraine, neuropathic pain and proliferative diseases
MX2021013817A (es) Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
Brazzelli et al. Indolent systemic mastocytosis treated with narrow‐band UVB phototherapy: study of five cases
BR112022027069A2 (pt) Agente terapêutico para o câncer de mama
Sherman Early clinical studies of novel therapies for thyroid cancers
RU2015108755A (ru) Комбинация ингибитора pik3 и ингибитора с-мет
MX2020008610A (es) Agente terapeutico para carcinoma hepatocelular.
Xu et al. Endoplasmic reticulum stress targeted therapy for breast cancer
Forder et al. Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat
BR112023022735A2 (pt) Derivado de fosfonila e composição e aplicação farmacêutica do mesmo
Minuti et al. Protein kinase inhibitors to treat non-small-cell lung cancer
MX2018006329A (es) Agente terapeutico para cancer de mama.
AR128079A1 (es) Composición farmacéutica que comprende un compuesto de quinazolina
BR112022008677A2 (pt) Terapia de combinação com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidina-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida